intellia logo

The 2020 Nobel Prize in Chemistry has been awarded “for the development of a method for genome editing.”

Jennifer Doudna, Ph.D.
Co-founder, Intellia Therapeutics

“Have you ever been in an environment full of intellectual people? Now combine that with CRISPR/Cas9. Greatness at full potential.”

Denisse
Sr. Associate Scientist, Mass Spectrometry

“My father-in-law, Ben – or as Pam calls him, Benny – lost his battle with AML far too soon, which makes me especially proud to work for a company that is striving to provide curative treatments for that disease, among others.”

Stacey
Associate Director, Finance
Pam, whose husband passed away from acute myeloid leukemia

“Benny had a way of making everything OK. I miss his smile.”

Read more

“UKATPA’s objective is to raise awareness and give support to patients, caregivers and health care professionals.”

Vince
UKATPA Treasurer

Vince and David, friends and colleagues living with ATTR

“The biggest surprise to us was how many people have amyloidosis and don’t have anyone to talk to.”
– David, UKATPA Secretary

Read more

Intellia has received a grant from the Bill & Melinda Gates Foundation to develop curative CRISPR/Cas9 in vivo sickle cell disease treatments. Read more.

Funding will be used to develop safe, scalable and accessible non-viral treatments for sickle cell patients.
News Update
March 30, 2021
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
Quick Links
Events & Presentation
Events & Presentation
Stock Information
Stock Information
Press<br />Releases
Press
Releases
Overview

Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.

Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.

Learn About Our Mission
Programs & Pipeline

Each one of us together for patients

We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.

View Our In Vivo and Ex Vivo Programs
Join Us.
See how you can change life stories with genome editing
Learn More
Follow Us on Social Media
April 12, 2021

#ICYMI Intellia CSO, @LauraSepplore, was recently a guest on @BioAgilytix’s podcast, Molecular Moments, discussing her path from Argentina to the U.S., gene therapy vs. #genomeediting and the work we’re doing at Intellia. Listen here: https://t.co/vnXn2AC4Wd https://t.co/UKS9Jgwn5N

View on Twitter
April 12, 2021

A warm welcome to Georgia Keresty, Ph.D., M.P.H., to Intellia’s Board of Directors! We look forward to drawing on her insights as a successful industry leader to help advance our programs toward the clinic: https://t.co/2SFlI7zpuD #CRISPR https://t.co/sLOMnf1LTN

View on Twitter
Menu